News – Page 13 – Sanaria

The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine

December 9, 2008 By Matt Feldman In Publications No Comments

We are developing a radiation attenuated Plasmodium falciparum sporozoite (PfSPZ) malaria vaccine. An important step was to determine the minimum dose of irradiation required to adequately attenuate each sporozoite. This was studied in the Plasmodium yoelii rodent model system. Exposure to 100 Gy completely attenuated P. yoelii sporozoites (PySPZ).

Sanaria and Sanaria’s CEO, Dr. Stephen L. Hoffman, featured in Esquire magazine

December 2, 2008 By Matt Feldman In In The Media No Comments

In the December, 2008 issue of Esquire, read the great discussion of malaria and the critical, innovative work that Sanaria is doing to develop new vaccines.

Sanaria and TI Pharma collaborators at Radboud University Nijmegen Medical Centre and Leiden University Medical Centre publish the first report of genetically attenuated P. falciparum sporozoites

October 30, 2008 By Matt Feldman In Press Releases No Comments

Every day 2000 children die from malaria in Africa alone. The infec6on is transmi9ed from human to human by bi6ng mosquitoes and remains one of the world’s most devasta6ng diseases. Despite many years of effort a vaccine is s6ll not available but is urgently needed, if we are to make an impact on this enormous problem.

Gene Disruption of Plasmodium falciparum p52 Results in Attenuation of Malaria Liver Stage Development in Cultured Primary Human Hepatocytes

October 28, 2008 By Matt Feldman In Publications No Comments

Difficulties with inducing sterile and long lasting protective immunity against malaria with subunit vaccines has renewed interest in vaccinations with attenuated Plasmodium parasites. Immunizations with sporozoites that are attenuated by radiation (RAS) can induce strong protective immunity both in humans and rodent models of malaria.

Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant

July 29, 2008 By Matt Feldman In Press Releases No Comments

Sanaria Inc., a privately held company in Rockville, Maryland, and the University of Maryland Biotechnology Institute (UMBI) announced the receipt of a multi-year Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

Malaria vaccine developer Sanaria Inc. receives the Technology Council of Maryland’s Emerging Company of the Year Award.

May 15, 2008 By Matt Feldman In Press Releases No Comments

Sanaria Inc. was named Emerging Company of the Year at the annual Technology Council of Maryland’s Tech Awards Celebration honoring the state’s technology leaders and organizations.

Self-Experimenters: Malaria Vaccine Maven Baits Irradiated Mosquitoes with His Own Arm

March 12, 2008 By Matt Feldman In In The Media No Comments

Stephen Hoffman has given years of sweat—and lots of blood—on his quest to stop a global killer. Read the full article in Scientific American.|

Sanaria, Top Institute Pharma, Radboud University Nijmegen Medical Centre and Leiden University Medical Center enter into $23.6 million research agreement

January 16, 2008 By Matt Feldman In Press Releases No Comments

Today Top Institute Pharma announces a highly promising research project that is aimed at the development of a malaria vaccine. This TI Pharma project will be an expansion of extremely promising findings from previous studies.

Sanaria featured in The New York Times, The Soul of a New Vaccine

December 11, 2007 By Matt Feldman In In The Media No Comments

The sign on the wall reads “Emergency Response Procedures for a Mosquito Release.”

Among them are “Do Not Leave the Room or Open Any Doors!!!” and “Do Not Panic!”

Everything in the room is white, including the lab coats and surgical masks — for sterility, yes, but also the better to see a mosquito. Hanging next to the sign, in vivid Coast Guard orange, is the last line of defense, a brace of fly swatters.

This room, the mosquito dissection lab, in an unassuming biotech park in the Washington suburbs, is at the heart of one of the most controversial |

Sanaria CEO, Dr. Stephen L. Hoffman, interviewed on Al Jazeera English’s: The Pulse

December 3, 2007 By Matt Feldman In In The Media No Comments

Despite millions of dollars being spent on research there is no vaccine available against one of the world's biggest killer diseases -- Malaria. The Pulse looks at the parasite that has proved too complex for scientists and visits a clinical trial in Tanzania, which is showing unusual promise.

December 1, 2007 By Matt Feldman In In The Media No Comments

In the latest Forbes' Wolfe Emerging Tech Report, Sanaria's new manufacturing facilities are featured as part of our efforts to develop a new vaccine against malaria.

Adel A. F. Mahmoud, M.D., Ph.D joins Sanaria Board of Directors

November 5, 2007 By Matt Feldman In News No Comments

Sanaria is pleased to announce that Adel A. F. Mahmoud, M.D., Ph.D, of the Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University and former President of Merck Vaccines, was elected to Sanaria's Board of Directors.

Whole parasite malaria vaccine to be manufactured for clinical trials

October 29, 2007 By Matt Feldman In In The Media No Comments

Sanaria Inc. and the PATH Malaria Vaccine Initiative has officially opened a one-of-a- kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.

Researchers aim to use mosquitoes to bite back at malaria

October 28, 2007 By Matt Feldman In In The Media No Comments

A US scientist is leading an international team of researchers using an army of blood- sucking mosquitoes to produce a potentially potent vaccine against malaria.

Malaria vaccine plant takes a gamble

October 27, 2007 By Matt Feldman In In The Media No Comments

In a nondescript office park tucked between a hospital and a strip mall thrive hundreds of thousands of the most infectious malaria-carrying mosquitoes ever born. They will be dissected for the motherlode that they carry -- baby malaria parasites, fodder for a new malaria vaccine.

Sanaria, PATH Malaria Vaccine Initiative Open Manufacturing Facility For Producing World’s First “Whole-Parasite” Malaria Vaccine

October 26, 2007 By Matt Feldman In Press Releases No Comments

Sanaria Inc. and the PATH Malaria Vaccine Initiative today officially opened a one-of-a-kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.

New front launched in war on malaria

October 26, 2007 By Matt Feldman In In The Media No Comments

With $29.3M from the Gates Foundation, Rockville company opens plant today.

Fred Binka, Sanaria Advisory Board Member, featured in Newsweek

September 28, 2007 By Matt Feldman In In The Media No Comments

Read the full Newsweek article: “Giving Globally: The Search for Solutions“|

Sanaria featured in National Geographic magazine

July 7, 2007 By Matt Feldman In In The Media No Comments

Read the full story: Bedlam in the Blood, Malaria (Membership required). NatGeo Article|

Sanaria featured in ‘Kill or Cure’ documentary

April 27, 2007 By Matt Feldman In In The Media No Comments

Kill or Cure? The Malaria Vaccine takes viewers into the starkly different worlds of two cutting-edge investigators who may be moving us tantalizingly close to an achievement unheard of in the history of immunizations - an effective vaccine against a parasitic disease.

Contact Us

We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Email:

sanaria@sanaria.com

Social: